Oncodesign Precision Medicine
Conducts research and development work on new therapeutic and diagnostic tools.
Launch date
Employees
Market cap
€99.7m
Enterprise valuation
€102m (Public information from Dec 2022)
Share price
€14.42 AlONC.PA
Company register number 892226762
Dijon Bourgogne-Franche-Comté (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 10.0m | 14.0m | 20.0m | 26.0m | 25.0m | 32.0m | 52.0m |
| % growth | - | 40 % | 43 % | 30 % | (4 %) | 28 % | 63 % |
| EBITDA | (2.0m) | 3.0m | (2.0m) | 3.0m | 4.0m | (1.0m) | 3.0m |
| % EBITDA margin | (20 %) | 21 % | (10 %) | 12 % | 16 % | (3 %) | 6 % |
| Profit | - | 5.0m | (3.0m) | 1.0m | 2.0m | (1.0m) | 2.0m |
| % profit margin | - | 36 % | (15 %) | 4 % | 8 % | (3 %) | 4 % |
| EV / revenue | - | 5.7x | 2.4x | 2.7x | 4.0x | 2.1x | 0.9x |
| EV / EBITDA | - | 26.7x | -23.5x | 23.3x | 25.3x | -68.0x | 16.3x |
| R&D budget | 5.0m | 10.0m | 20.0m | 20.0m | 30.0m | - | - |
| R&D % of revenue | 50 % | 71 % | 100 % | 77 % | 120 % | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$4.7m | Series C | ||
$24.7m | Grant | ||
| N/A | €12.3m Valuation: €44.5m | IPO | |
N/A | Grant | ||
* | N/A | Buyout | |
* | €6.0m | Post IPO Debt | |
* | N/A | N/A | Post IPO Equity |
* | €1.7m | Grant | |
* | €3.9m | Post IPO Debt | |
| Total Funding | €28.4m | ||
Recent News about Oncodesign Precision Medicine
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.